Antibody-drug conjugates (ADCs) represent a promising approach in oncology due to their ability to deliver cytotoxic drugs selectively to cancer cells. By combining the tumor-targeting specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic agents, ADCs are engineered to improve therapeutic outcomes while minimizing damage to healthy tissue. However, their therapeutic efficacy is not only dependent on the specific antibody or drug payload but also on a critical parameter known as the drug–antibody ratio (DAR).
DAR refers to the average number of drug molecules conjugated to each antibody molecule. This number plays a significant role in determining the balance between efficacy and safety for ADCs. High DAR levels have shown potential in enhancing the cytotoxic effect within tumors, but they also introduce challenges in drug conjugation, clearance, solubility, and safety.
Recent developments in ADC technology are pushing for higher DAR values to intensify antitumor effects. Trastuzumab Emtansine, for example, has a DAR of approximately 3.5, while newer ADCs such as Enhertu reach around 8. This shift from earlier-generation ADCs (typically 2–4) demonstrates a broader ADC platform evolution. The rationale for higher DARs is clear—more drug molecules can be delivered to the tumor per antibody, improving overall potency against targets such as HER2 (human epidermal growth factor receptor 2).
However, this approach comes with challenges. Many ADC-targeted tumor antigens are expressed at low levels, meaning that increasing the DAR does not always improve efficacy because the target antigen may be limited. In tumour types with low antigen density, increased DAR may not correspond to increased benefit. Furthermore, high DARs can alter molecular size, increase hydrophobicity, and reduce monomer content, all of which affect pharmacokinetics and quality control.
The chemical nature of the drug payload profoundly affects ADC behaviour. High-DAR ADCs are often associated with increased hydrophobicity due to dense conjugation sites on lysine-linked ADCs or cysteine residues. This can lead to aggregation and faster clearance from circulation. To monitor these effects, hydrophobic interaction chromatography and reversed-phase high-performance liquid chromatography are frequently used to assess ADC stability.
Researchers also rely on liquid chromatography coupled with Mass spectrometry to characterise ADC structure, evaluate drug candidates, and confirm the Drug-to-Antibody Ratio. Complementary methods such as hydrophilic interaction chromatography, UV/Vis spectroscopy, and ion mobility characterization are part of a robust analytical toolkit for ADC quality control.
The faster clearance is problematic because it limits the time the ADC can circulate and effectively target tumor cells. Consequently, the potential benefits of a high DAR are often counterbalanced by reduced therapeutic exposure. Hydrophobicity-related challenges also make it difficult to deliver the ADC in high concentrations without inducing adverse side effects.
To address the hydrophobicity and pharmacokinetic limitations of high-DAR ADCs, researchers are exploring site-specific conjugation chemistries. Traditional ADCs often use random conjugation techniques, which can lead to variability in the location and number of drugs attached to the antibody. This lack of precision contributes to inconsistent drug release and variable efficacy.
Site-specific conjugation aims to attach drug molecules to predetermined sites on the antibody. By using well-characterized amino acid residues, such as cysteines or engineered sites on the antibody, scientists can improve the consistency and safety profile of the ADC. Site-specific conjugation offers the potential to produce ADCs with high DARs without introducing the same level of hydrophobicity or instability as seen with random conjugation methods.
These innovative chemistries have the potential to extend the half-life of ADCs in circulation, improving their biodistribution and ultimately increasing their therapeutic index. Some successful site-specific approaches include the use of cysteine-based conjugation or enzymatic techniques that modify select lysine residues, allowing for more controlled and predictable drug loading.
Another innovative solution to the challenges associated with high DAR ADCs involves self-assembled ADC technology. Researchers have developed a method using a Holliday junction tetramer, a four-armed DNA structure, to regulate the construction of ADCs. This self-assembly approach allows for better control over the number of drug molecules attached to each antibody. Unlike traditional chemical conjugation methods, self-assembly can enable the creation of ADCs with a precise DAR while mitigating the hydrophobicity issues that are common with high drug loads.
By using the Holliday junction as a scaffold, multiple antibodies can be linked to several drug molecules in a highly organized manner. This level of control leads to improved stability, reduced aggregation, and more favorable pharmacokinetics compared to traditional high-DAR ADCs. This method could significantly enhance the therapeutic window of ADCs, offering the benefits of high DAR without the corresponding risks.
Another promising area of innovation is the development of polymer linkers to improve the efficacy and stability of ADCs with high DARs. Traditionally, ADCs use short peptide or chemical linkers to attach the drug payload to the antibody. These linkers, while effective, can contribute to rapid clearance and suboptimal delivery of the drug to the tumor. Polymer linkers, such as Fleximer™ or PEG (polyethylene glycol) chains, are being explored as alternatives that can provide a more flexible and stable attachment.
Polymer linkers offer several advantages. First, they help to shield the hydrophobicity of high-DAR ADCs by creating a more water-soluble structure, which improves the ADC's pharmacokinetics. Second, these linkers can serve as "spacers" that position the drug payload further away from the antibody, reducing steric hindrance and potentially improving binding to tumor cells. Finally, polymer linkers can be designed to release the drug payload in a controlled manner once the ADC has entered the tumor environment, ensuring more efficient drug delivery and reducing off-target effects.
Researchers are also investigating the use of branched linkers that incorporate multiple drug molecules. These linkers could enable the construction of ultra-high DAR ADCs with improved solubility and reduced aggregation, potentially overcoming the limitations of traditional high-DAR ADCs.
The development of antibody–drug conjugates continues to evolve through precision chemistry, advanced analytics, and innovative engineering. The integration of Mass spectrometry, liquid chromatography, and related analytical methods allows researchers to ensure stability, uniform DAR distribution, and consistent quality control across batches. These refinements in drug conjugation and structural analysis are setting new standards for monoclonal antibody–based therapeutics in modern oncology.
Biointron’s catalog products for in vivo research can be found at Abinvivo, where we have a wide range of Antibody-Drug Conjugates, Bispecific Antibodies, Benchmark Positive Antibodies, Isotype Negative Antibodies, and Anti-Mouse Antibodies. Contact us to find out more at info@biointron.comor +86 400-828-8830 / +1(732)790-8340.
References:
Jin, S., Zhuang, X., Xu, Y., Nie, G., Chen, S., & Pan, L. (2024). DNA self-assembly-mediated high drug-antibody ratio ADC platform for targeted tumor therapy and imaging. Nano Today, 58, 102459. https://doi.org/10.1016/j.nantod.2024.102459
Emmert, M. H., Bottecchia, C., Barrientos, R. C., Feng, Y., Holland-Moritz, D., Hughes, G. J., Lam, Y., Regalado, E. L., Ruccolo, S., Sun, S., Chmielowski, R., Yang, C., Lévesque, F., Raymond, K., Haley, M. (2024). Organic Process Research & Development 28(8), 3326-3338. https://doi.org/10.1021/acs.oprd.4c00226
Chis, A. A., Dobrea, C. M., Arseniu, A. M., Frum, A., Rus, L., Cormos, G., Georgescu, C., Morgovan, C., Butuca, A., Gligor, F. G., & Vonica-Tincu, A. L. (2024). Antibody–Drug Conjugates—Evolution and Perspectives. International Journal of Molecular Sciences, 25(13). https://doi.org/10.3390/ijms25136969
Two popular topics discussed at the 2026 BIO International Convention were devel……
AI is changing antibody discovery, but model performance depends on the quality ……
Antibody discovery has become increasingly sequence-rich. Display technologies, ……
Biointron, a leading contract research organization specializing in antibody dis……
You can also contact us on the Scientist and Science Exchange marketplaces.
